$13,000.00
In Stock
Kimmtrak is a novel drug for the treatment of ocular melanoma (uveal melanoma). Kimmtrak is designed to target cancer cells while minimizing damage to healthy tissue. Tebentafusp is a bispecific immune conjugate that simultaneously binds to T cells and melanoma cells, helping to destroy them.
This is a new type of immunotherapy that activates and programs the immune system to detect and destroy malignant cells.
The drug is used to treat inoperable, or metastatic, uveal melanoma.
Active ingredient: tebentafusp
Prescription medicine
Storage temperature 2-8 degrees
The drug is delivered from Germany
